Risk of vascular anomalies with Down syndrome

Pediatrics

Volumn 121, Issue 1, 2008, Pages

  Greene, Arin K ^a   Kim, Sendia ^a   Rogers, Gary F ^a   Fishman, Steven J ^a   Olsen, Bjorn R ^a   Mulliken, John B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Down syndrome; Endostatin; Hemangioma; Malformations; Vascular anomalies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ENDOSTATIN;

ANGIOGENESIS; ARTICLE; BINOMIAL DISTRIBUTION; BIRTH DEFECT; CALCULATION; CHILD; CHROMOSOME 21; CONFIDENCE INTERVAL; CONGENITAL BLOOD VESSEL MALFORMATION; DATA BASE; DISEASE ASSOCIATION; DOWN SYNDROME; FEMALE; GENE DOSAGE; HEMANGIOMA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK REDUCTION; SOLID TUMOR; VASCULAR TUMOR;

ABNORMALITIES, MULTIPLE; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PROBABILITY; REGISTRIES; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; VASCULAR MALFORMATIONS;

EID: 38049048634     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-1316     Document Type: Article

References (81)

1. Torfs CP, Christianson RE. Anomalies in Down syndrome individuals in a large population-based registry. Am J Med Gen. 1998;77:431-438
2. Watanabe H, Fujiyama A, Hattori M, et al. DNA sequence and comparative analysis of chimpanzee chromosome 22. Nature. 2004;429:382-388
3. Barlow GM, Chen XN, Shi ZY, et al. Down syndrome congenital heart disease: a narrowed region and a candidate gene. Genet Med. 2001;3:91-101
4. Ermak G, Morgan TE, Davies KJ. Chronic overexpression of calcineurin inhibitory gene DSCR1 (adapt78) is associated with Alzheimer's disease. J Biol Chem. 2001;276:38787-38794
5. Rachidi M, Lopes C, Delezoide AL, Delabar JM. C21orf5, a human candidate gene for brain abnormalities and mental retardation in Down syndrome. Cytogenet Genome Res. 2006;112:16-22
6. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165-169
7. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359:1019-1025
8. Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature. 2000;405:311-319
9. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285
10. Feldman AL, Restifo NP, Alexander HR, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. 2000;60:1503-1506
11. Feldman AL, Tamarkin L, Paciotti GF, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2000;6:4628-4634
12. Zorick TS, Mustacchi Z, Yumi S, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumors. Eur J Hum Gen. 2001;9:811-814
13. Dourmishev A, Miteva L, Mitev V, Pramatarov K, Schwartz RA. Cutaneous aspects of Down syndrome. Pediatr Dermatol. 2000;66:420-424
14. Singh RV, Suys S, Yeh JS, Campbell DA, Broome JC. Spinal intramedullary cavernous angioma in a patient with Down's syndrome. Clin Neurol Neurosurg. 1993;95:550-558
15. Nagasaka T, Shiozawa Z, Kobayashi M, Shindo K, Tsunoda S, Amino A. Autopsy findings in Down's syndrome with cerebrovascular disorder. Clin Neuropathol. 1996;15:145-149
16. Gaggero R, Donati PT, Curia R, De Negri M. Occlusion of unilateral carotid artery in Down syndrome. Brain Dev. 1996;18:81-83
17. Park M, Raila FA, Russel WF. Moyamoya disease in an adult with Down syndrome: comparison of magnetic resonance angiography and conventional angiography. South Med J. 1996;89:89-92
18. Ram SP. Kasabach-Merritt syndrome and Down's syndrome. J R Soc Med. 1997;90:159-160
19. Patankar T, Prasad S, Joshi A, Deshmukh H. Jejunal angiomatoses causing small bowel obstruction in a patient with Down syndrome: a case report. J Postgrad Med. 1998;44:16-18
20. Kassardjian Z, Lebret T, Mellot F, et al. Major complex pelvic arteriovenous malformation in a patient with Down syndrome. Urol Int. 2002;69:1454-1459
21. Yamazaki M, Okawa A, Aramomi MA, Hashimoto M, Masaki Y, Koda M. Fenestration of vertebral artery at the craniovertebral junction in Down syndrome: a case report. Spine. 2004;29:E551-E554
22. Yamazaki M, Koda M, Yoneda M, Aiba A, Moriya H. Anomalous vertebral artery at the craniovertebral junction in a patient with Down syndrome: case report. J Neurosurg Spine. 2004;1:338-341
23. Tatekawa Y, Muraji T, Tsugawa C. Ileo-ceacal arterio-venous malformation associated with extrahepatic portal hypertension: a case report. Pediatr Surg Int. 2005;21:835-838
24. Erguven M, Deveci M, Turgut T. Moyamoya disease and Down syndrome. Indian J Pediatr. 2005;72:697-699
25. Sabde S, Tullu MS, Lahiri KR, Vaswani RK. Moyamoya syndrome in a child with Down syndrome. Arch Med Res. 2005;36:421-424
26. Murphy AM, Brenner C, Lynch SA. Agenesis of the corpus callosum with interhemispheric cyst, hepatic haemangioma and trisomy 21. Clin Dysmorphol. 2006;15:149-151
27. Mutton DE, Alberman E, Ide R, Bobrow M. Results of first year (1989) of a national register of Down's syndrome in England and Wales. BMJ. 1991;303:1295-1297
28. National Birth Defects Prevention Network. Birth defect surveillance data from selected states, 1989-1996. Teratology. 2000;61:86-158
29. Bivings L. Spontaneous regression of angiomas in children. J Pediatr. 1954;45:643-647
30. Holmdahl K. Cutaneous hemangiomas in premature and mature infants. Acta Paediatr. 1955;44:370-379
31. Jacobs AH. Strawberry hemangiomas. Calif Med. 1957;86:8-10
32. Jacobs AH, Cahn RL. Birthmarks. Pediatr Ann. 1976;5:743-758
33. Osburn K, Schosser RH, Everett MA. Congenital pigmented and vascular lesions in newborn infants. J Am Acad Derm. 1987;16:788-792
34. Forrester MB, Merz RD. Descriptive epidemiology of cystic hygroma: Hawaii, 1986 to 1999. South Med J. 2004;97:631-636
35. Malone FD, Ball RH, Nyberg DA, et al. First-trimester septated cystic hygroma: prevalence, natural history, and pediatric outcome. Obstet Gynecol. 2005;106:288-294
36. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412-422
37. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93:2357-2364
38. Zhang L, Lin X, Wang W, et al. Circulating levels of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg. 2005;116:200-204
39. Koizumi T, Shiraishi T, Hagihara N, Tabuchi K, Hayashi T, Kawano T. Expression of vascular endothelial growth factors and their receptors in and around intracranial arteriovenous malformations. Neurosurgery. 2002;50:117-124
40. Marler JJ, Fishman SJ, Kilroy SM, et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics. 2005;116:38-45
41. Sure U, Freman S, Bozinov O, Benes L, Siegel AM, Bertalanffy H. Biological activity of adult cavernous malformations: a study of 56 patients. J Neurosurg. 2005;102:342-347
42. Hashimoto T, Wu Y, Lawton MT, Yang GY, Barbaro NM, Young WL. Coexpression of angiogenic factors in brain arteriovenous malformations. Neurosurgery. 2005;56:1058-1065
43. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature. 2006;441:595-600
44. Gardiner K, Costa AC. The proteins of human chromosome 21. Am J Med Genet. 2006;142:196-205
45. Ambler CA, Nowicki JL, Burke AC, Bautch VL. Assembly of trunk and limb blood vessels involves extensive migration and vasculogenesis of somite-derived angioblasts. Dev Biol. 2001;234:352-364
46. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69:4-10
47. Hajitou A, Grignet-Debrus C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002;16:1802-1804
48. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci U S A. 2004;25:8005-8010
49. Gu JW, Shparago M, Tan W, Bailey AP. Tissue endostatin correlates inversely with capillary network in rat heart and skeletal muscle. Angiogenesis. 2006;9:93-99
50. Sund M, Hamano Y, Sugimoto, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A. 2005;102:2934-2939
51. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J. 2002;21:1535-1544
52. Marneros AG, Olsen BR. Physiologic role of collagen XVIII and endostatin. FASEB J. 2005;19:716-728
53. Kuo CJ, LaMontagne KR, Garcia-Cardena G, et al. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol. 2001;152:1233-1246
54. Schmidt A, Addicks K, Bloch W. Opposite effects of endostatin on different endothelial cells. Cancer Biol Ther. 2004;3:1162-1166
55. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest. 2001;107:745-752
56. Khan ZA, Melero-Martin JM, Wu X, Paruchuri S, Mulliken JB, Bischoff J. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique responses to endostatin. Blood. 2006;108:915-921
57. Minami T, Horiuchi K, Miura M, et al. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem. 2004;279:50537-50554
58. Chan B, Greenan G, McKeon F, Ellenberger T. Identification of a peptide fragment of DSRC1 that competitively inhibits calcineurin activity in vitro and in vivo. Proc Natl Acad Sci U S A. 2005;102:13075-13080
59. Yao YG, Duh EJ. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis. Biochem Biophy Res Comm. 2004;321:648-656
60. Qin L, Zhao D, Liu X, et al. Down syndrome candidate region 1 isoform1 mediates angiogenesis through the calcineurin-NFAT pathway. Mol Cancer Res. 2006;4:811-820
61. Drake CJ, LaRue A, Ferrara N, Little CD. VEGF regulates cell behavior during vasculogenesis. Dev Biol. 2000;224:178-188
62. Argraves WS, Drake CJ. Genes critical to vasculogenesis as defined by systemic analysis of vascular defects in knockout mice. Anat Rec A Discov Mol Cell Evol Biol. 2005;286:875-884
63. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-494
64. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395
65. Drake C, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci U S A. 1995;92:7657-7661
66. Flamme I, von Reutern M, Drexler HCA, Syed-Ali S, Risau W. Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased permeability without alterations of embryonic pattern formation. Dev Dyn. 1995;171:399-414
67. Cleaver O, Tonissen KF, Saha MS, Krieg PA. Neovascularization of the Xenopus embryo. Dev Dyn. 1997;210:66-77
68. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. 1998;2:549-558
69. Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol. 1987;16:899-906
70. Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn. 2001;220:1-17
71. Schroeder JA, Jackson LF, Lee DC, Camenisch TD. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J Mol Med. 2003;81:392-403
72. Carvalhaes LS, Gervasio OL, Guatimosim C, et al. Collagen XVIII/Endostatin is associated with the epithelial-mesenchymal transformation in the atrioventricular valves during cardiac development. Devel Dyn. 2006;235:132-142
73. Lambrechts D, Carmeliet P. Genetics in zebrafish, mice, and humans to dissect congenital heart disease: insights in the role of VEGF. Curr Top Dev Biol. 2004;62:189-224
74. Martyn U, Schilte-Merker S. Zebrafish neuropilins are differentially expressed and interact with vascular endothelial growth factor during embryonic vascular development. Dev Dyn. 2004;42:33-42
75. Lambrechts D, Devriendt K, Driscoll DA, et al. Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study. J Med Genet. 2005;42:519-522
76. Lee YM, Cope JJ, Ackermann GE, et al. Vascular endothelial growth factor receptor signaling is required for cardiac valve formation in zebrafish. Dev Dyn. 2006;235:29-37
77. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development. 2000;126:1149-1159
78. Nasevicius A, Larson J, Ekker SL. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast. 2000;17:294-301
79. Dor Y, Camenisch TD, Itin A, et al. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development. 2001;128:1531-1538
80. Drake CJ, Wessels A, Trusk T, Little CD. Elevated vascular endothelial cells growth factor affects mesocardial morphogenesis and inhibits normal heart bending. Dev Dyn. 2006;235:10-18
81. Chang CP, Neilson JR, Bayle JH, et al. A field of myocardialendocardial NFAT signaling underlies heart valve morphogenesis. Cell. 2004;118:649-663